Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Baxalta Incorporated et al v. Genentech, Inc. et al
Case Number:
1:17-cv-00509
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 21, 2022
Judge Dyk Explains Takeda Loss In IP Fight Over Hemlibra
U.S. Circuit Judge Timothy B. Dyk has unsealed his opinion in a Delaware federal court case explaining why he found a Takeda Pharmaceutical Co. Ltd. unit's antibody patent was too broad to meet the enablement requirement, ultimately letting Roche subsidiary Genentech off the hook for infringing with its blockbuster hemophilia drug Hemlibra.
-
January 14, 2022
Takeda Loses Patent Fight Over Roche's Hemlibra Drug
A federal court in Delaware has said that a Takeda Pharmaceutical Co. Ltd. unit's patent covering antibodies isn't valid after all, sinking the Japanese multinational's infringement case against the Roche-owned company that makes the blockbuster hemophilia drug Hemlibra.